Cite
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.
MLA
Chen, Evan C., et al. “Outcomes of Antifungal Prophylaxis for Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax.” Leukemia & Lymphoma, vol. 63, no. 8, Aug. 2022, pp. 1934–41. EBSCOhost, https://doi.org/10.1080/10428194.2022.2047964.
APA
Chen, E. C., Liu, Y., Harris, C. E., Winer, E. S., Wadleigh, M., Lane, A. A., Vedula, R. S., Lindsley, R. C., Copson, K. M., Charles, A., Marty, F., Neuberg, D., DeAngelo, D. J., Stone, R. M., Luskin, M. R., Issa, N. C., & Garcia, J. S. (2022). Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leukemia & Lymphoma, 63(8), 1934–1941. https://doi.org/10.1080/10428194.2022.2047964
Chicago
Chen, Evan C., Yiwen Liu, Courtney E. Harris, Eric S. Winer, Martha Wadleigh, Andrew A. Lane, Rahul S. Vedula, et al. 2022. “Outcomes of Antifungal Prophylaxis for Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax.” Leukemia & Lymphoma 63 (8): 1934–41. doi:10.1080/10428194.2022.2047964.